- Home
- DJT vs GRFS Comparison
DJT vs GRFS Comparison
Compare DJT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJT
- GRFS
- Stock Information
- Founded
- DJT 2021
- GRFS 1940
- Country
- DJT United States
- GRFS Spain
- Employees
- DJT N/A
- GRFS N/A
- Industry
- DJT Computer Software: Programming Data Processing
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- DJT Technology
- GRFS Health Care
- Exchange
- DJT Nasdaq
- GRFS Nasdaq
- Market Cap
- DJT 5.0B
- GRFS 5.1B
- IPO Year
- DJT N/A
- GRFS 2006
- Fundamental
- Price
- DJT $18.80
- GRFS $7.05
- Analyst Decision
- DJT
- GRFS
- Analyst Count
- DJT 0
- GRFS 0
- Target Price
- DJT N/A
- GRFS N/A
- AVG Volume (30 Days)
- DJT 3.8M
- GRFS 1.2M
- Earning Date
- DJT 05-25-2025
- GRFS 07-28-2022
- Dividend Yield
- DJT N/A
- GRFS N/A
- EPS Growth
- DJT N/A
- GRFS 283.33
- EPS
- DJT N/A
- GRFS 0.24
- Revenue
- DJT $3,618,800.00
- GRFS $7,467,006,939.00
- Revenue This Year
- DJT N/A
- GRFS $8.45
- Revenue Next Year
- DJT N/A
- GRFS $7.08
- P/E Ratio
- DJT N/A
- GRFS $35.68
- Revenue Growth
- DJT N/A
- GRFS 9.41
- 52 Week Low
- DJT $11.75
- GRFS $5.79
- 52 Week High
- DJT $61.00
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- DJT 37.49
- GRFS 33.47
- Support Level
- DJT $19.62
- GRFS $7.13
- Resistance Level
- DJT $23.97
- GRFS $7.81
- Average True Range (ATR)
- DJT 1.05
- GRFS 0.22
- MACD
- DJT 0.39
- GRFS -0.12
- Stochastic Oscillator
- DJT 23.05
- GRFS 1.29
About DJT Trump Media & Technology Group Corp. Common Stock
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.